Normal view MARC view ISBD view

Long-acting antiretrovirals and HIV treatment adherence. [Review]

MedStar author(s):

Citation: The Lancet. HIV. 10(5):e332-e342, 2023 05.PMID: 37062293Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | ReviewSubject headings: *Anti-HIV Agents | *HIV Infections | Anti-Retroviral Agents/tu [Therapeutic Use] | HIV Infections/dt [Drug Therapy] | HIV Infections/et [Etiology] | Humans | Injections, Intramuscular/ae [Adverse Effects] | Rilpivirine/ae [Adverse Effects] | Year: 2023 ISSN:

2352-3018

Name of journal: The lancet. HIVAbstract: Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART. Copyright © 2023 Elsevier Ltd. All rights reserved.All authors: Archary M, Decloedt E, Gandhi M, Geng EH, Mellors JW, Mofenson LM, Nachega JB, Nachman S, Rawat A, Scarsi KK, Scott RK, Wilson LFiscal year: FY2023 Digital Object Identifier:

https://dx.doi.org/10.1016/S2352-3018(23)00051-6

Date added to catalog: 06/01/2023

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	37062293	Available		37062293

Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART. Copyright © 2023 Elsevier Ltd. All rights reserved.

English